Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, Sabbatini P, Mendelson D, Schwartz L, Gettinger S, Psyrri A, Cedarbaum JM, Spriggs DR. Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors. Clinical Cancer Research 2010, 16: 358-366. PMID: 20028764, PMCID: PMC4211604, DOI: 10.1158/1078-0432.ccr-09-2103.Peer-Reviewed Original ResearchConceptsAdvanced solid tumorsSolid tumorsDrug-related grade 3Vascular endothelial growth factor trapDose of afliberceptDose-escalation studyDose-proportional increaseInjection site reactionsPhase 1 studyManageable side effectsVascular endothelial growth factorWarrants further evaluationFavorable pharmacokinetic profileProgression of diseaseNovel antiangiogenic agentsEndothelial growth factorCommon toxicitiesStable diseasePulmonary embolismCerebral ischemiaSubcutaneous dosesSafety profileSingle doseSite reactionsSubcutaneous formulationManagement of Patients with Advanced Non-Small Cell Lung Cancer
Triano LR, Deshpande H, Gettinger SN. Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs 2010, 70: 167-179. PMID: 20108990, DOI: 10.2165/11532200-000000000-00000.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerEpidermal growth factor receptorGrowth factor receptorOverall survivalLung cancerThird-line treatmentFirst-line chemotherapyFactor receptorManagement of patientsVascular endothelial growth factorQuality of lifeEndothelial growth factorMedian survivalSystemic therapyRandomized trialsTraditional chemotherapySmall molecule inhibitorsFDA approvalUS FDAChemotherapyKey mediatorGrowth factorAdditional agents